Navigation Links
German MedSys Project Adopts Genedata Phylosopher for Research Informatics

Genedata’s Target Discovery System Chosen as Central Data Management Solution for German Medical Systems Biology Initiative to Study Infectious Diseases of Fungal Pathogens.

(PRWEB) April 27, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Phylosopher has been adopted by the “Dr. Jekyll & Mr. Hyde” project, which is funded by the German Medical Systems Biology (MedSys) initiative. The multidisciplinary “Dr. Jekyll & Mr. Hyde” project, which is comprised of universities, research institutes, clinics, and industrial partners, aims at identifying novel targets for diagnostics, patient risk assessment, and therapy of infectious disease caused by the opportunistic fungal pathogen Candida albicans. Genedata Phylosopher will be the central data management infrastructure integrating and interpreting the high-throughput experimental data generated within the consortium, focusing on next-generation sequencing, microarray, proteome, and metabolite data.

“We decided to partner with Genedata because they offered a product-based solution for centralized data management,” explained Prof. U. Bilitewski, Dr. Jekyll & Mr. Hyde project coordinator at the Helmholtz Centre for Infection Research (Braunschweig, Germany). “Using Phylosopher we are able to perform –omics data and next-generation sequencing data integration and analysis in one system. This greatly helps us understand infection mechanisms of Candida.”

Candida albicans is the single most prevalent fungal pathogen causing up to 70% of all fungal hospital-acquired infections and is a major problem in intensive care units. While anti-mycotics are often given prophylactically to combat this problem, this leads to the selection of resistant strains requiring new therapeutic strategies. In the commensal state C. albicans asymptomatically colonize the host with the host protected from infection. Knowledge of molecular mechanisms, which prevent the pathogenicity of C. albicans, is still in its infancy. The “Dr. Jekyll and Mr. Hyde” project aims at identifying biomarkers that could guide a therapeutic intervention.

"The Dr. Jekyll & Mr. Hyde project is a network of excellent scientific institutions, and Genedata is proud to be part of this consortium,” said Dr. Othmar Pfannes, CEO of Genedata. “Having this interdisciplinary consortium chose Genedata Phylosopher as their central data management and analysis infrastructure demonstrates Genedata’s continued leadership in delivering tailored solutions based on a strong product portfolio and professional services for biomarker discovery for novel diagnostic and therapeutic approaches.”

About MedSys Initiative and Dr. Jekyll & Mr. Hyde Project
The “Dr. Jekyll and Mr. Hyde” project is granted within the German Medical Systems Biology program ( The project aims at generating a systems understanding of the key mechanisms leading to the protection of the host, i.e. preventing the pathogenic state of Candida albicans. The multidisciplinary consortium of universities, research institutes, clinics, and enterprises will focus on the study of host-pathogen interactions by assessing, from a Systems Biology perspective, both the response of the host to Candida albicans, and of this opportunistic pathogen to the host under commensal and pathogenic conditions.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher, Genedata Screener, Genedata Expressionist, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan, and the US.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing?
2. Paternity Testing Without Father and Mother? The German Company bj-diagnostik Investigates that Two babies Separately Left at Charity Institution are Siblings
3. New silicon-germanium nanowires could lead to smaller, more powerful electronic devices
4. Health Robotics to Launch Germanys Installations of i.v.STATION(TM) at Charite-Universitatsmedizin Berlin
5. German Alliance for Industrial Biotechnology Debuts in Montreal
6. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
7. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
8. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
9. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
10. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
11. CPA Acquires Renowned German Patent Research Specialist, SVPG
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... environment are paramount. Insertion points for in-line sensors can represent a weak spot ... InTrac 781/784 series of retractable sensor housings , which are designed to ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
(Date:10/23/2015)... BERLIN and GOLETA, California ... the HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce ... and eye tracking data captured during interactive real-world tasks ... plug and play integration of their established wearable solutions ... researchers to synchronize gaze behavior captured with SMI ...
Breaking Biology News(10 mins):